Mei 2016
31
Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, Leverve X. 2004. Metformin
inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study.
Biochem J 382: 877-84.
Jurkiewicz E, Chelstowska S, Pakula-Kosciesza I, Malczyk K, Nowak K, Bekiesinska-Figatowska M.
Proton MR Spectroscopy in Patients with Leigh Syndrome. 2011. Neuroradiol J 24: 424-428
Lake NJ, Compton AG, Rahman S, Thorburn DR. 2015. Leigh Syndrome: One disorder, more than 75
monogenic causes, Ann Neurol. 2015 Oct 27 epub
Lee EH, Ahn MS, Hwang JS, Ryu KH, Kim SJ, Kim SH. A Korean female patient with thiamine-
responsive pyruvate dehydrogenase complex deficiency due to a novel point mutation (Y161C) in
the PDHA1 gene. 2006. J Korean Med Sci 21:800-804.
Lindahl b. 2013. The Story of Growth Differentiation Factor 15: Another Piece of the Puzzle. Clin
Chem 59:1550-1552
Luís PB, Ruiter JP, Aires CC, Soveral G, de Almeida IT, Duran M, Wanders RJ, Silva MF. 2007.
Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-
oxoglutarate-driven oxidative phosphorylation. Biochim Biophys Acta 1767: 1126-33.
McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, Chinnery PF, Ramesh V.
2008. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase
gamma (POLG1). Arch Dis Child 93: 151-3.
Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR. 2003. Differential effects of typical and
atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res 26: 951-9.
Montini G, Malaventura C, Salviati L. 2008. Early coenzyme Q10 supplementation in primary
coenzyme Q10 deficiency. N Engl J Med 358:2849–2850.
Mottin S, Laporte P, Cespuglio R. 2003. Inhibition of NADH oxidation by chloramphenicol in the
freely moving rat measured by picosecond time-resolved emission spectroscopy. J Neurochem
84:633-42.
Pessayre D, Manzouri A, Haouzi D, Fromenty B. 1999. Hepatotoxicity due to mitochondrial
dysfunction. Cell Biol Toxicol 15: 367-73.
Rabier D, Diry C, Rotig A, Rustin P, Heron B, Bardet J, Parvy P, Ponsot G, Marsac C, Saudubray JM,
Munnich A, Kamoun P. Persistent hypocitrullinaemia as a marker for mtDNA NARP T 8993 G
mutation? J Inherit Metab Dis. 21:216–9.
Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR. 1996.
Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 39:343–351.
Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, Giardina B. 2004. Mitochondrial
respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands:
biochemical and pharmacological implications. Biochem Biophys Res Commun 319: 967-73.
Scarpelli M, Todeschini A, Rinaldi F, Rota S2 Padovani A, Filosto M. Strategies for treating
mitochondrial disorders: An update. Mol Genet Metab 113:253-60
